New research has suggested that the expiration of biologics patents will be the factor that positively impacts US pharma the most this year.
List view / Grid view
Filter the results
15 June 2016 | By Victoria White, Digital Content Producer
The proceeds will fund Phase II development of AAI202 - a novel antibiotic combination designed to treat drug-resistant Gram-negative bacterial infections...